There was a risk of shortages due to worldwide shortages of the product
Until next 9, the Ministry of Health will complete the distribution of more than 400,000 units of fast-acting analogue insulin, used in the treatment of type 1 diabetes.
The drug was bought after five months of negotiations with the pharmaceutical sector and after two failed attempts. It’s just that two previous negotiating sessions – in August last year and January this year – did not receive any proposals.
html[data-range=”xlarge”] figure image img.img-3e24095550799071060b974bc9e122f6ru3y5l47 { width: 774px; height: 774px; }HTML[data-range=”large”] figure image img.img-3e24095550799071060b974bc9e122f6ru3y5l47 { width: 548px; height: 548px; }HTML[data-range=”small”] image figure img.img-3e24095550799071060b974bc9e122f6ru3y5l47, html[data-range=”medium”] figure figure img.img-3e24095550799071060b974bc9e122f6ru3y5l47 { width: 564px; height: 564px; }
The Ministry of Health has anticipated the delivery of insulin due to the risk of shortages caused by the worldwide shortage of the product. This load of 400,000 units adds to that of 1.3 million doses purchased in an emergency and which will guarantee the supply of SUS and more than 60,000 people who provide assistance in the Unified Health System.
According to the Ministry of Health, the most consumed regular insulins, indicated for patients with type 2 and other types of diabetes, are “adequate stock”. Rapid-acting insulin analogs were incorporated into the SUS in 2017 after approval by Conitec, the National Commission for the Incorporation of Technologies into the Unified Healthcare System.
Source: Terra

Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.